Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes
about
Extracting information from the text of electronic medical records to improve case detection: a systematic reviewCardiovascular effects of basal insulinsInsulin resistance as a physiological defense against metabolic stress: implications for the management of subsets of type 2 diabetesReduced risk of lung cancer with metformin therapy in diabetic patients: a systematic review and meta-analysisComparative cardiovascular morbidity and mortality in patients taking different insulin regimens for type 2 diabetes: a systematic reviewRecent HbA1c values and mortality risk in type 2 diabetes. population-based case-control studyIncidence of chronic kidney disease among people with diabetes: a systematic review of observational studies.Comparative risk of major cardiovascular events associated with second-line antidiabetic treatments: a retrospective cohort study using UK primary care data linked to hospitalization and mortality records.Diabetic peripheral neuropathy in ambulatory patients with type 2 diabetes in a general hospital in a middle income country: a cross-sectional studyNovel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes.Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetesMetformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders.Left ventricular diastolic function in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor- a pilot study.Cardiovascular impact of drugs used in the treatment of diabetesDiabetes burden and diabetes distress: the buffering effect of social support.A real world comparison of sulfonylurea and insulin vs. incretin-based treatments in patients not controlled on prior metformin monotherapy.Treatment with insulin (analogues) and breast cancer risk in diabetics; a systematic review and meta-analysis of in vitro, animal and human evidence.All-Cause and Cause-Specific Mortality among Users of Basal Insulins NPH, Detemir, and Glargine.Determinants of mortality in patients with type 2 diabetes: a review.Association between Insulin Monotherapy versus Insulin plus Metformin and the Risk of All-Cause Mortality and Other Serious Outcomes: A Retrospective Cohort StudyDiabetes and Breast Cancer Subtypes.Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical ConsiderationsDrug treatment of type 2 diabetes mellitus in patients for whom metformin is contraindicated.Antidiabetic treatment, stroke severity and outcomeDrug-subphenotype interactions for cancer in type 2 diabetes mellitus.Safety of antidiabetes medications: An update.Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes.Experiences of diabetes self-management: a focus group study among Australians with type 2 diabetes.Obviating much of the need for insulin therapy in type 2 diabetes mellitus: A re-assessment of insulin therapy's safety profile.Cancer risk of sulfonylureas in patients with type 2 diabetes mellitus: A systematic review.The effects of dual-therapy intensification with insulin or dipeptidylpeptidase-4 inhibitor on cardiovascular events and all-cause mortality in patients with type 2 diabetes: A retrospective cohort study.Changes in Glycemic Control and Body Weight After Initiation of Dapagliflozin or Basal Insulin Supported Oral Therapy in Type 2 Diabetes: A Primary Care Database Study.Metformin and cancer in type 2 diabetes: a systematic review and comprehensive bias evaluation.Patterns of anti-diabetic medication use in patients with type 2 diabetes mellitus in England and Wales.Impact of the use of anti-diabetic drugs on survival of diabetic dialysis patients: a 5-year retrospective cohort study in Taiwan.Cardiovascular events and all-cause mortality with insulin versus glucagon-like peptide-1 analogue in type 2 diabetes.Efficacy and safety of sitagliptin/metformin fixed-dose combination compared with glimepiride in patients with type 2 diabetes: A multicenter randomized double-blind study.The Effect of Metformin Use on Left Ventricular Ejection Fraction and Mortality Post-Myocardial Infarction.Effectiveness of insulin therapy in people with Type 2 diabetes in the Hoorn Diabetes Care System.Insulin-Treated Patients with Diabetes Mellitus Undergoing Emergency Abdominal Surgery Have Worse Outcomes than Patients Treated with Oral Agents.
P2860
Q26766556-D547B8C7-A812-431C-A5D8-C55A06E68E84Q26800249-D9AF76BE-9CC4-4257-890D-234E4B4442AFQ26866924-EEE13EEC-9802-416F-BA81-C844E7EFEBE4Q27025309-28C0C764-0C01-4479-9710-69A31759D929Q28082405-9FB8C2F1-2564-4B17-B564-FFA5DF312078Q28534542-7AF2D744-56C7-4905-AC5A-C210C9845510Q30238531-BB7A013E-9BD8-4A6F-B175-D237F7135860Q31095975-0EFBE407-4E04-4647-A3EA-803D24C8991BQ33553232-B182EB84-492D-421C-A773-818921D4A798Q33835709-E5BDF485-948F-4D61-B756-E2948DA4EAB3Q34109319-99ED968A-18C7-4F31-8D29-659BB066F67BQ34135248-2B535180-B49E-457E-BB4E-6096936236F5Q34283308-49520A2D-885A-45B0-BEE9-4288DE84DCADQ34383575-A9F9692F-071F-4117-AB5E-CFB345AECDE9Q34598307-220D2A5B-F8A2-4E98-B45A-D12785D68F6BQ35073584-F14B7553-5998-4E96-9042-9A24FE950205Q35937961-8DD96631-B748-4DCB-82E3-63771ED3D07BQ35974970-89B818B2-F524-4DD5-AFFF-5F1F24D01F46Q35986709-1459F892-7E6F-480D-9AF1-7A1F7EB85F90Q36010556-F1150CA7-E510-4A28-BBE0-EC0E3DB15B1DQ36246468-D22FCBF0-D136-4623-B058-35635A9C11E5Q37011769-343F428A-7CE7-49F0-AFF9-BD3F02B95683Q37509313-26CFFD1C-A111-4540-8ED4-A9B2CC839324Q38205762-1837E8E8-03CA-4703-ABE8-BBD3F0165B20Q38388443-3F708508-A4C9-4F16-AECA-1B1F28BFC93CQ38395221-156E44CA-48AF-41D0-871B-1B0A24C96E07Q38524435-DBE1BC66-D9D7-48A8-B262-4570710D847BQ38562906-95E66DCA-088E-4C66-AF12-E8F5749E2DAAQ38841043-45154EEC-3EA4-4693-A752-64CC647065BAQ38858585-A0A59752-84EE-47C7-8ACC-2F6B695C5FC0Q38885733-86335D5C-62FC-469F-9097-39FF5CF96C59Q38903825-B48DD8DC-A8CA-4E72-853A-89DD025D6CBBQ38999875-B23EB652-17FE-4CBC-A186-BE8193F0530AQ39376180-7DA50343-C8C5-4697-8F8D-1817A4257E93Q39418202-DAE8C98F-9747-46E4-A942-E958D619D657Q39741688-B0248A63-38D2-4F86-B861-DEE9386CCE59Q40492085-A4936A9F-1FFB-4D6E-BB46-CFF73C7B8DCCQ40842440-EDF30891-67A1-403E-A0AB-B0F0E9BDEA74Q40869844-41A8A9C4-5419-475C-BD5C-91127E1750A3Q40888974-316CBC69-65D3-4E5B-99A0-C3ADED949CEA
P2860
Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Mortality and other important ...... c therapies in type 2 diabetes
@ast
Mortality and other important ...... c therapies in type 2 diabetes
@en
type
label
Mortality and other important ...... c therapies in type 2 diabetes
@ast
Mortality and other important ...... c therapies in type 2 diabetes
@en
prefLabel
Mortality and other important ...... c therapies in type 2 diabetes
@ast
Mortality and other important ...... c therapies in type 2 diabetes
@en
P2093
P2860
P356
P1476
Mortality and other important ...... c therapies in type 2 diabetes
@en
P2093
Chris D Poole
Christopher Ll Morgan
Craig J Currie
John R Peters
Marc Evans
P2860
P304
P356
10.1210/JC.2012-3042
P407
P577
2013-01-31T00:00:00Z